William Edward Boden, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Ischemia | 66 | 2022 | 2114 | 9.490 |
Why?
|
| Coronary Artery Disease | 83 | 2022 | 6213 | 7.510 |
Why?
|
| Angioplasty, Balloon, Coronary | 56 | 2021 | 1859 | 6.170 |
Why?
|
| Myocardial Revascularization | 36 | 2022 | 839 | 5.410 |
Why?
|
| Coronary Artery Bypass | 46 | 2022 | 2376 | 4.900 |
Why?
|
| Myocardial Infarction | 125 | 2022 | 11323 | 4.850 |
Why?
|
| Cardiovascular Agents | 34 | 2022 | 863 | 4.180 |
Why?
|
| Angina Pectoris | 38 | 2022 | 1010 | 4.160 |
Why?
|
| Niacin | 13 | 2019 | 113 | 3.970 |
Why?
|
| Hypolipidemic Agents | 16 | 2019 | 611 | 3.460 |
Why?
|
| Cholesterol, HDL | 19 | 2020 | 1817 | 3.380 |
Why?
|
| Angina, Unstable | 33 | 2022 | 931 | 3.310 |
Why?
|
| Acute Coronary Syndrome | 28 | 2022 | 2232 | 2.760 |
Why?
|
| Coronary Disease | 49 | 2022 | 6127 | 2.690 |
Why?
|
| Platelet Aggregation Inhibitors | 35 | 2021 | 2994 | 2.490 |
Why?
|
| Electrocardiography | 72 | 2018 | 6386 | 2.160 |
Why?
|
| Dyslipidemias | 7 | 2022 | 843 | 2.080 |
Why?
|
| Hypertriglyceridemia | 5 | 2022 | 292 | 2.040 |
Why?
|
| Coronary Angiography | 48 | 2022 | 4383 | 1.950 |
Why?
|
| Calcium Channel Blockers | 16 | 2020 | 698 | 1.850 |
Why?
|
| Cardiovascular Diseases | 32 | 2022 | 14075 | 1.800 |
Why?
|
| Diltiazem | 21 | 2001 | 135 | 1.700 |
Why?
|
| Vasodilator Agents | 12 | 2017 | 1010 | 1.660 |
Why?
|
| Myocardial Perfusion Imaging | 9 | 2022 | 618 | 1.500 |
Why?
|
| Nitrates | 8 | 2017 | 259 | 1.470 |
Why?
|
| Adrenergic beta-Antagonists | 23 | 2020 | 1224 | 1.430 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 9 | 2019 | 1178 | 1.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 19 | 2022 | 3097 | 1.370 |
Why?
|
| Coronary Vessels | 12 | 2022 | 2964 | 1.360 |
Why?
|
| Randomized Controlled Trials as Topic | 43 | 2022 | 9488 | 1.340 |
Why?
|
| Exercise Test | 26 | 2020 | 2125 | 1.330 |
Why?
|
| Ischemia | 12 | 2022 | 1934 | 1.310 |
Why?
|
| Drug-Eluting Stents | 7 | 2016 | 735 | 1.290 |
Why?
|
| Ticlopidine | 15 | 2016 | 884 | 1.230 |
Why?
|
| Coronary Stenosis | 10 | 2018 | 804 | 1.200 |
Why?
|
| Humans | 372 | 2022 | 708843 | 1.130 |
Why?
|
| Triglycerides | 13 | 2022 | 2564 | 1.050 |
Why?
|
| Thrombolytic Therapy | 13 | 2018 | 2163 | 1.020 |
Why?
|
| Treatment Outcome | 96 | 2022 | 61932 | 1.010 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 11 | 2011 | 648 | 0.990 |
Why?
|
| Nitroglycerin | 3 | 2015 | 328 | 0.970 |
Why?
|
| Fractional Flow Reserve, Myocardial | 3 | 2022 | 246 | 0.960 |
Why?
|
| Aspirin | 16 | 2018 | 3138 | 0.920 |
Why?
|
| Risk Assessment | 43 | 2020 | 23284 | 0.910 |
Why?
|
| Drug Therapy, Combination | 33 | 2018 | 6562 | 0.910 |
Why?
|
| Fibrinolytic Agents | 9 | 2014 | 2129 | 0.870 |
Why?
|
| Atherosclerosis | 13 | 2022 | 3228 | 0.870 |
Why?
|
| Vasodilation | 2 | 2017 | 968 | 0.870 |
Why?
|
| Secondary Prevention | 10 | 2018 | 1505 | 0.850 |
Why?
|
| Coronary Circulation | 5 | 2021 | 1652 | 0.830 |
Why?
|
| Renal Insufficiency, Chronic | 10 | 2022 | 1938 | 0.830 |
Why?
|
| Eicosapentaenoic Acid | 6 | 2022 | 535 | 0.820 |
Why?
|
| Diabetes Mellitus | 8 | 2021 | 5348 | 0.790 |
Why?
|
| Practice Guidelines as Topic | 25 | 2019 | 7487 | 0.780 |
Why?
|
| Clinical Trials as Topic | 22 | 2022 | 8024 | 0.760 |
Why?
|
| Translating | 1 | 2020 | 137 | 0.760 |
Why?
|
| Stents | 12 | 2021 | 3312 | 0.730 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2019 | 128 | 0.720 |
Why?
|
| Disease Management | 6 | 2022 | 2536 | 0.700 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 4810 | 0.690 |
Why?
|
| Exercise Tolerance | 5 | 2018 | 802 | 0.690 |
Why?
|
| Cholesterol, LDL | 13 | 2020 | 2351 | 0.680 |
Why?
|
| Risk Factors | 76 | 2022 | 69553 | 0.670 |
Why?
|
| Syndrome | 14 | 2021 | 3177 | 0.670 |
Why?
|
| Unnecessary Procedures | 1 | 2021 | 442 | 0.650 |
Why?
|
| Diabetes Mellitus, Type 2 | 13 | 2020 | 10857 | 0.640 |
Why?
|
| Middle Aged | 154 | 2022 | 213752 | 0.640 |
Why?
|
| Time Factors | 53 | 2021 | 41038 | 0.640 |
Why?
|
| Myocardial Reperfusion | 3 | 2008 | 349 | 0.640 |
Why?
|
| Risk Reduction Behavior | 6 | 2022 | 1110 | 0.630 |
Why?
|
| Lipoproteins | 3 | 2018 | 914 | 0.630 |
Why?
|
| Aged | 125 | 2022 | 161488 | 0.630 |
Why?
|
| Anticholesteremic Agents | 8 | 2018 | 964 | 0.620 |
Why?
|
| Male | 178 | 2022 | 349524 | 0.610 |
Why?
|
| Delayed-Action Preparations | 8 | 2019 | 963 | 0.600 |
Why?
|
| Female | 189 | 2022 | 375205 | 0.590 |
Why?
|
| Reimbursement Mechanisms | 1 | 2021 | 665 | 0.560 |
Why?
|
| Tyrosine | 4 | 2008 | 1477 | 0.560 |
Why?
|
| Thrombosis | 6 | 2018 | 2840 | 0.550 |
Why?
|
| Health Care Reform | 2 | 2017 | 1248 | 0.520 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2016 | 161 | 0.510 |
Why?
|
| Chelation Therapy | 1 | 2013 | 65 | 0.510 |
Why?
|
| Diabetic Angiopathies | 4 | 2015 | 846 | 0.500 |
Why?
|
| Insulin | 3 | 2016 | 6648 | 0.500 |
Why?
|
| Prognosis | 37 | 2021 | 28919 | 0.500 |
Why?
|
| Health Expenditures | 2 | 2019 | 2240 | 0.490 |
Why?
|
| Peripheral Arterial Disease | 4 | 2019 | 1206 | 0.490 |
Why?
|
| Heart Rate | 15 | 2018 | 4094 | 0.480 |
Why?
|
| Coronary Restenosis | 3 | 2012 | 425 | 0.480 |
Why?
|
| Acetanilides | 3 | 2011 | 163 | 0.470 |
Why?
|
| Heart Diseases | 4 | 2012 | 2759 | 0.460 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2020 | 6765 | 0.460 |
Why?
|
| Androgens | 1 | 2020 | 1216 | 0.460 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 575 | 0.450 |
Why?
|
| Quality of Life | 24 | 2022 | 11594 | 0.450 |
Why?
|
| Follow-Up Studies | 41 | 2021 | 39038 | 0.440 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 2734 | 0.440 |
Why?
|
| Chelating Agents | 1 | 2013 | 407 | 0.440 |
Why?
|
| Multicenter Studies as Topic | 10 | 2010 | 1513 | 0.440 |
Why?
|
| Combined Modality Therapy | 14 | 2018 | 8896 | 0.440 |
Why?
|
| Coronary Care Units | 4 | 2008 | 208 | 0.430 |
Why?
|
| Survival Rate | 16 | 2021 | 13202 | 0.410 |
Why?
|
| Piperazines | 6 | 2013 | 2532 | 0.410 |
Why?
|
| Verapamil | 3 | 2001 | 252 | 0.410 |
Why?
|
| Double-Blind Method | 24 | 2021 | 11877 | 0.400 |
Why?
|
| Cause of Death | 6 | 2019 | 3497 | 0.390 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 1819 | 0.390 |
Why?
|
| Severity of Illness Index | 22 | 2020 | 16008 | 0.390 |
Why?
|
| Testosterone | 2 | 2021 | 2352 | 0.390 |
Why?
|
| Lipoproteins, HDL | 5 | 2018 | 649 | 0.380 |
Why?
|
| Endpoint Determination | 5 | 2011 | 623 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2019 | 1478 | 0.380 |
Why?
|
| Simvastatin | 6 | 2019 | 356 | 0.380 |
Why?
|
| Goals | 1 | 2014 | 642 | 0.360 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 1999 | 0.360 |
Why?
|
| Gemfibrozil | 4 | 2003 | 29 | 0.360 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2011 | 234 | 0.360 |
Why?
|
| Anticoagulants | 6 | 2009 | 4293 | 0.350 |
Why?
|
| Coronary Thrombosis | 4 | 2011 | 487 | 0.350 |
Why?
|
| Stroke | 20 | 2022 | 9256 | 0.350 |
Why?
|
| Hyperlipidemias | 3 | 2022 | 796 | 0.340 |
Why?
|
| Echocardiography, Stress | 4 | 2015 | 131 | 0.340 |
Why?
|
| Cardiology | 5 | 2021 | 1638 | 0.340 |
Why?
|
| Perioperative Care | 2 | 2017 | 1067 | 0.330 |
Why?
|
| Predictive Value of Tests | 17 | 2022 | 15252 | 0.330 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 235 | 0.330 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 3316 | 0.320 |
Why?
|
| Hospitals, Veterans | 4 | 2002 | 407 | 0.320 |
Why?
|
| Laboratories | 1 | 2011 | 430 | 0.320 |
Why?
|
| Cost-Benefit Analysis | 10 | 2022 | 5235 | 0.320 |
Why?
|
| United States | 34 | 2022 | 67165 | 0.310 |
Why?
|
| Stroke Volume | 7 | 2016 | 4522 | 0.310 |
Why?
|
| Fibrinolysis | 2 | 2007 | 350 | 0.310 |
Why?
|
| Exercise Therapy | 1 | 2014 | 901 | 0.310 |
Why?
|
| Hyperglycemia | 2 | 2013 | 1343 | 0.310 |
Why?
|
| Patient Admission | 3 | 2013 | 1398 | 0.310 |
Why?
|
| Creatine Kinase | 14 | 2005 | 713 | 0.290 |
Why?
|
| Decision Trees | 4 | 2020 | 521 | 0.290 |
Why?
|
| Survival Analysis | 18 | 2020 | 10507 | 0.290 |
Why?
|
| Heart Conduction System | 2 | 2001 | 1030 | 0.290 |
Why?
|
| Digoxin | 3 | 2000 | 244 | 0.290 |
Why?
|
| Health Status | 9 | 2022 | 4015 | 0.290 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 3936 | 0.290 |
Why?
|
| Tachycardia, Ventricular | 2 | 2011 | 1177 | 0.290 |
Why?
|
| Registries | 6 | 2021 | 7989 | 0.280 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2021 | 823 | 0.280 |
Why?
|
| Postoperative Complications | 7 | 2017 | 15053 | 0.280 |
Why?
|
| Guideline Adherence | 7 | 2019 | 2315 | 0.280 |
Why?
|
| Television | 1 | 2008 | 410 | 0.280 |
Why?
|
| United States Department of Veterans Affairs | 7 | 2022 | 866 | 0.270 |
Why?
|
| Recurrence | 18 | 2018 | 8255 | 0.260 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2017 | 756 | 0.260 |
Why?
|
| Thiophenes | 3 | 2013 | 597 | 0.260 |
Why?
|
| Microcirculation | 1 | 2009 | 1301 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2020 | 2042 | 0.250 |
Why?
|
| Government Regulation | 1 | 2008 | 542 | 0.240 |
Why?
|
| History, 21st Century | 4 | 2018 | 1569 | 0.240 |
Why?
|
| Acute Disease | 13 | 2005 | 7158 | 0.240 |
Why?
|
| Antihypertensive Agents | 3 | 2019 | 2046 | 0.230 |
Why?
|
| Lipids | 2 | 2009 | 3246 | 0.230 |
Why?
|
| Insurance, Health | 2 | 2019 | 2475 | 0.230 |
Why?
|
| Incidence | 12 | 2021 | 20320 | 0.230 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 2090 | 0.230 |
Why?
|
| Evidence-Based Medicine | 7 | 2017 | 3690 | 0.220 |
Why?
|
| Hippocratic Oath | 1 | 2021 | 16 | 0.220 |
Why?
|
| Hemorrhage | 8 | 2018 | 3235 | 0.220 |
Why?
|
| Hypertension | 9 | 2019 | 8161 | 0.220 |
Why?
|
| Cardiology Service, Hospital | 1 | 2004 | 253 | 0.220 |
Why?
|
| Hospitals, Urban | 1 | 2004 | 514 | 0.220 |
Why?
|
| Blood Glucose | 2 | 2016 | 6255 | 0.220 |
Why?
|
| Proportional Hazards Models | 15 | 2020 | 12292 | 0.220 |
Why?
|
| Prospective Studies | 24 | 2021 | 50597 | 0.220 |
Why?
|
| History, 20th Century | 4 | 2018 | 2837 | 0.210 |
Why?
|
| Comorbidity | 11 | 2019 | 10339 | 0.200 |
Why?
|
| Drug Therapy | 2 | 2010 | 518 | 0.200 |
Why?
|
| Felodipine | 2 | 1997 | 3 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 11239 | 0.200 |
Why?
|
| Aged, 80 and over | 20 | 2022 | 58184 | 0.200 |
Why?
|
| Phenethylamines | 1 | 2000 | 103 | 0.190 |
Why?
|
| Brugada Syndrome | 2 | 2011 | 97 | 0.190 |
Why?
|
| Blood Platelets | 1 | 2010 | 2485 | 0.180 |
Why?
|
| Peptides | 4 | 2008 | 4424 | 0.180 |
Why?
|
| Referral and Consultation | 3 | 2022 | 3436 | 0.180 |
Why?
|
| Veterans | 5 | 2022 | 2288 | 0.180 |
Why?
|
| Risk | 8 | 2018 | 9641 | 0.180 |
Why?
|
| Preventive Medicine | 2 | 2017 | 259 | 0.180 |
Why?
|
| Troponin | 4 | 2011 | 505 | 0.170 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2019 | 296 | 0.170 |
Why?
|
| Hospitals | 1 | 2011 | 3290 | 0.170 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2008 | 500 | 0.170 |
Why?
|
| Research Design | 8 | 2019 | 5833 | 0.170 |
Why?
|
| Creatine Kinase, MB Form | 3 | 2020 | 221 | 0.170 |
Why?
|
| Exercise | 4 | 2018 | 5251 | 0.170 |
Why?
|
| Cardiomegaly | 3 | 1992 | 653 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2007 | 2716 | 0.170 |
Why?
|
| Isoenzymes | 11 | 2005 | 1812 | 0.170 |
Why?
|
| Sodium Channel Blockers | 1 | 2019 | 187 | 0.170 |
Why?
|
| Enalapril | 2 | 1997 | 316 | 0.160 |
Why?
|
| Diagnosis, Differential | 5 | 2011 | 13274 | 0.160 |
Why?
|
| Coronary Sinus | 1 | 2017 | 75 | 0.160 |
Why?
|
| Vascular Diseases | 2 | 2019 | 1154 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 2019 | 242 | 0.160 |
Why?
|
| Outpatients | 2 | 2021 | 1349 | 0.160 |
Why?
|
| Oxygen Consumption | 2 | 2017 | 1928 | 0.150 |
Why?
|
| Blood Pressure | 10 | 2019 | 8528 | 0.150 |
Why?
|
| Life Style | 4 | 2019 | 3636 | 0.150 |
Why?
|
| Canada | 6 | 2015 | 1915 | 0.150 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2001 | 1085 | 0.150 |
Why?
|
| Internationality | 1 | 2022 | 1002 | 0.150 |
Why?
|
| Administration, Sublingual | 1 | 2015 | 55 | 0.150 |
Why?
|
| Hypogonadism | 1 | 2021 | 753 | 0.140 |
Why?
|
| Brachiocephalic Veins | 1 | 2015 | 21 | 0.140 |
Why?
|
| Hospital Mortality | 6 | 2013 | 5095 | 0.140 |
Why?
|
| Brain Ischemia | 4 | 2018 | 3260 | 0.140 |
Why?
|
| Ontario | 1 | 2016 | 358 | 0.140 |
Why?
|
| Medicare | 1 | 2013 | 5691 | 0.140 |
Why?
|
| Disease Progression | 6 | 2011 | 13298 | 0.140 |
Why?
|
| Benzazepines | 3 | 1986 | 326 | 0.140 |
Why?
|
| Tablets | 1 | 2015 | 148 | 0.140 |
Why?
|
| Resource Allocation | 1 | 2017 | 342 | 0.140 |
Why?
|
| Azetidines | 2 | 2013 | 146 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 3 | 2001 | 1336 | 0.140 |
Why?
|
| Age Factors | 9 | 2019 | 18712 | 0.140 |
Why?
|
| Haptoglobins | 1 | 2016 | 168 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2021 | 767 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2016 | 9754 | 0.140 |
Why?
|
| North America | 4 | 2013 | 1174 | 0.140 |
Why?
|
| Heart Failure | 7 | 2022 | 10040 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 423 | 0.140 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2015 | 291 | 0.130 |
Why?
|
| Bioprosthesis | 2 | 1994 | 618 | 0.130 |
Why?
|
| Cardiac Care Facilities | 2 | 2011 | 34 | 0.130 |
Why?
|
| Clinical Protocols | 5 | 2019 | 1470 | 0.130 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 3562 | 0.130 |
Why?
|
| Adult | 42 | 2020 | 211041 | 0.130 |
Why?
|
| Retrospective Studies | 23 | 2021 | 71483 | 0.130 |
Why?
|
| Medical History Taking | 2 | 2015 | 804 | 0.130 |
Why?
|
| Cholesterol | 2 | 2013 | 2866 | 0.130 |
Why?
|
| Sex Factors | 6 | 2020 | 10566 | 0.130 |
Why?
|
| Medication Adherence | 3 | 2022 | 2019 | 0.120 |
Why?
|
| Chronic Disease | 6 | 2022 | 8992 | 0.120 |
Why?
|
| Pericarditis | 2 | 1985 | 114 | 0.120 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1999 | 867 | 0.120 |
Why?
|
| Echocardiography | 4 | 2022 | 5139 | 0.120 |
Why?
|
| Apolipoprotein A-II | 1 | 1992 | 45 | 0.120 |
Why?
|
| Connecticut | 2 | 2004 | 363 | 0.110 |
Why?
|
| Pacemaker, Artificial | 2 | 2010 | 762 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2018 | 1493 | 0.110 |
Why?
|
| Aerosols | 1 | 2015 | 689 | 0.110 |
Why?
|
| Societies, Scientific | 1 | 2013 | 212 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 1510 | 0.110 |
Why?
|
| Angioplasty | 2 | 2015 | 405 | 0.110 |
Why?
|
| Polysaccharides | 2 | 2009 | 991 | 0.110 |
Why?
|
| Early Diagnosis | 2 | 2015 | 1192 | 0.110 |
Why?
|
| Patient Transfer | 3 | 2008 | 759 | 0.110 |
Why?
|
| Diabetes Complications | 3 | 2011 | 1394 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1995 | 496 | 0.110 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 12447 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2022 | 39292 | 0.110 |
Why?
|
| Streptokinase | 1 | 1991 | 189 | 0.110 |
Why?
|
| Physician Executives | 1 | 2012 | 135 | 0.110 |
Why?
|
| Hospitals, Community | 3 | 2008 | 332 | 0.100 |
Why?
|
| Communication Barriers | 1 | 2014 | 364 | 0.100 |
Why?
|
| Radionuclide Ventriculography | 3 | 2002 | 40 | 0.100 |
Why?
|